Bortezomib (Velcade): A feasibility and phase II study in childhood relapsed acute lymphoblastic leukemia.

Trial Profile

Bortezomib (Velcade): A feasibility and phase II study in childhood relapsed acute lymphoblastic leukemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone; Methotrexate; Vincristine
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Dec 2015 Status changed from recruiting to completed, according to Netherlands Trial Register.
    • 10 Dec 2013 Interim pharmacokinetic results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
    • 29 Mar 2012 Actual initiation date (11 Jan 2010) added as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top